ArticleAmerican journal of translational research2026
Electro-acupuncture attenuates cyclophosphamide-induced premature ovarian insufficiency in rats through miRNA regulation and TGFβ/Smad pathway modulation.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the protective effects and molecular mechanisms of electro-acupuncture (EA) in a cyclophosphamide (CTX)-induced rat model of premature ovarian insufficiency (POI), focusing on ovarian microRNA (miRNA) regulation and TGFβ/Smad pathway modulation.
methodsTwenty-four female Sprague-Dawley rats were classified into four groups: Control, CTX, CTX + EA, and CTX + GnRHa (positive control). POI was induced by CTX injection. EA was applied at six acupoints for 15 min daily (days 10-25). Ovarian function was evaluated through estrous cycle monitoring, histology, follicle counting, and serum hormone assays (FSH, E2, AMH). Serum ALT, AST, BUN, and UA were measured to assess organ toxicity. Ovarian ultrastructure was analyzed by TEM. Differential miRNA expression was profiled by small RNA sequencing and validated by qRT-PCR. Pathway analysis (KEGG, GO) and TGFβ/Smad signaling evaluation (qRT-PCR, western blot) were performed.
resultsEA significantly improved body weight and ovarian index (P < 0.01 vs. CTX) and reduced CTX-induced hepatic and renal injury markers. Regular estrous cycles were restored in 83% of EA-treated rats. EA normalized FSH, E2, and AMH levels (P < 0.01 vs. CTX), restored follicle counts and ovarian morphology, and reversed subcellular damage observed under TEM. EA upregulated protective miRNAs (miR-145-3p, miR-25-3p) and inhibited aberrant TGFβ/Smad activation, revealing a miRNA-mediated mechanism underlying ovarian protection.
conclusionEA confers significant protection against CTX-induced POI by preserving ovarian structure, normalizing endocrine function, and regulating miRNA-TGFβ/Smad signaling, supporting its potential as a non-pharmacological therapy for ovarian preservation and fertility maintenance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.